<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2016</study_start_year><data_sharing_plan>IPD Sharing (as of April 2016): Undecided</data_sharing_plan><condition>Colorectal Neoplasms</condition><disease>Colorectal Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2213351</full_dataset_link><location>China</location><study_start_month>1</study_start_month><keyword>Vascular Endothelial Growth Factor A</keyword><keyword>Endostar</keyword><keyword>Endostar protein</keyword><keyword>Anti-angiogenesis Drugs</keyword><keyword>Endostatins</keyword><keyword>Thalidomide</keyword><keyword>Advanced Colorectal Cancer</keyword><repository>ECRIN MDR</repository><study_status>Not provided</study_status></additional><is_claimable>false</is_claimable><name>Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical</name><description>The purpose of this study is to determine whether Endostar pumping into vein with Thalidomide are more effective in the treatment of Advanced Colorectal Cancer (ACRC).</description><dates><creation>2016-01-15</creation></dates><accession>2213351</accession><cross_references><ClinicalTrials___gov>NCT02748772</ClinicalTrials___gov></cross_references></HashMap>